Drug Type T-lymphocyte cell therapy |
Synonyms PD-1 gene edited T cell(Chengdu MedGenCell), PD-1 knockout engineered T cells (Chengdu MedGenCell) |
Target- |
Mechanism Gene silencing, Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 09 Aug 2024 | |
Neoplasms | IND Application | CN | 19 Oct 2022 | |
metastatic non-small cell lung cancer | Discovery | CN | 26 Aug 2016 |